{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-024896","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.062573+00:00","generated_at":"2026-06-11T01:07:40.075146+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intas Pharmaceuticals files PGR petition challenging Atossa's endoxifen patent","bullets":["Intas Pharmaceuticals filed a Post-Grant Review petition with USPTO challenging Atossa's U.S. Patent No. 11,572,334.","Patent covers methods for making and using endoxifen.","Atossa intends to contest the PGR and believes the patent is valid and enforceable.","No assurance of prevailing; Intas will be estopped from raising certain arguments in future litigation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-024896","json":"https://secwatch.observer/filing/0001437749-23-024896.json","markdown":"https://secwatch.observer/filing/0001437749-23-024896.md","text":"https://secwatch.observer/filing/0001437749-23-024896.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923024896/0001437749-23-024896-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923024896/atos20230830_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T01:07:40.075146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}